ID

46169

Description

Principal Investigator: William L. Lowe, Jr, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA MeSH: Pregnancy https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000096 Low and high birth weight are not only major causes of neonatal morbidity and mortality, but epidemiological data have established an association between birth weight and later life risk of adult metabolic diseases. Fetal growth is determined by complex interactions between fetal genes and the maternal uterine environment. Subtle or overt variation in maternal glucose tolerance, which is, in part, genetically determined, is related to fetal size at birth. Moreover, new emerging data suggest that genetic variation in the fetus can impact maternal metabolism (e.g., blood pressure and glucose tolerance). Given the above, we are addressing the hypothesis that, during pregnancy, gene-environment interactions in the context of the maternal-fetal unit impact fetal size at birth and maternal metabolism. Genes that control fetal growth or maternal metabolism during pregnancy are largely unknown, so the first step to address our hypothesis will be to identify genetic variation that impacts fetal growth and maternal metabolism and to determine the interaction of that variation with the intrauterine and fetal environment. To accomplish this, we are performing genome wide association (GWA) mapping on a subset of ~37,000 DNA samples that were collected from mothers and their offspring as part of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. HAPO is a multicenter, international study in which high quality phenotypic data related to fetal growth and maternal glucose metabolism has been collected from 25,000 pregnant women of varied racial and socio-demographic backgrounds using standardized protocols that were uniform across centers. For these studies, we are genotyping 1,500 infants and their mothers of European descent, 1,250 Afro-Caribbean infants and mothers, 800 Hispanic (Mexican-American) infants and mothers, and 1200 Thai infants and mothers. Genotyping is being performed using the Illumina Human610 Quad (European ancestry participants), Human1M Duo (Afro-Caribbean and Hispanic participants), and Omni1-Quad_v1-0_B (Thai participants). The specific aims for the project are as follows: (1) To apply analytic approaches for conducting GWA mapping studies on quantitative phenotypes related to offspring size at birth (birth weight, ponderal index, head circumference and adiposity) allowing for other known influences such as gestational age, parity, and maternal weight gain. (2) To apply the above approaches to identify genetic variation that impacts maternal glucose tolerance at ~28 weeks of gestation (fasting glucose, glucose during an oral glucose tolerance test, and insulin sensitivity expressed as quantitative traits) allowing for other known influences such as maternal weight gain, parity and age. (3) To examine the interaction between maternal genes, the intrauterine environment, and fetal genes to identify interactions that modulate genetic regulation of size at birth and fetal genetic variation that impacts on maternal glucose tolerance. GWA mapping will provide initial evidence for association of specific SNPs with the quantitative traits outlined above. As low and high birth weight are not only major causes of neonatal morbidity and mortality but have also been associated with increased risk of metabolic diseases in adults, identification of genes that regulate fetal growth and maternal metabolism will provide novel information about the pathways that regulate these processes as well as important insight into susceptibility genes for chronic diseases like type 2 diabetes. The Version 1 (v1) dbGaP release will include data only from the Hispanic study participants. The Version 2 (v2) dbGaP release will include data from the Hispanic and European ancestry study participants. The Version 3 (v3) dbGaP release will include data from the Afro-Caribbean, Hispanic and European ancestry participants. The Version 4 (v4) dbGaP release will include data from all participants (i.e., Afro-Caribbean, Hispanic, European ancestry, and Thai participants). This study is part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to maternal metabolism and birthweight through large-scale genome-wide association studies of infants and their mothers at multiple international sites. Genotyping was performed at the Broad Institute of MIT and Harvard, and at CIDR of Johns Hopkins University, GENEVA genotyping centers. Data cleaning and harmonization was performed at the GEI-funded GENEVA Coordinating Center at the University of Washington.

Lien

dbGaP study=phs000096

Mots-clés

  1. 11/07/2022 11/07/2022 - Chiara Middel
  2. 12/10/2022 12/10/2022 - Adrian Schulz
  3. 29/01/2025 29/01/2025 - Akane Nishihara
Détendeur de droits

William L. Lowe, Jr, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Téléchargé le

29 janvier 2025

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

dbGaP phs000096 HAPO Maternal Glycemia and Birthweight GEI Study

Eligibility Criteria

Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
A pregnant woman was *ineligible* to participate in HAPO if any of the following exclusion criteria applied:
Description

Elig.phs000096.v4.p1.1

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
Age < 18 years, i.e., has not completed 18th year of life by the first interview.
Description

Elig.phs000096.v4.p1.2

Type de données

boolean

Alias
UMLS CUI [1,1]
C1298908
UMLS CUI [1,2]
C0001675
UMLS CUI [1,3]
C0001779
UMLS CUI [1,4]
C0205435
UMLS CUI [1,5]
C0021822
Planning to deliver at another hospital or location.
Description

Elig.phs000096.v4.p1.3

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301732
UMLS CUI [1,2]
C1384485
UMLS CUI [1,3]
C1547118
Date of last menstrual period is not certain AND no ultrasound estimation from 6-24 weeks of gestational age is available or will be available.
Description

Elig.phs000096.v4.p1.4

Type de données

boolean

Alias
UMLS CUI [1,1]
C0425932
UMLS CUI [1,2]
C0087130
UMLS CUI [1,3]
C1298908
UMLS CUI [1,4]
C0470187
UMLS CUI [1,5]
C0041618
UMLS CUI [1,6]
C4323880
UMLS CUI [1,7]
C0730522
Unable to complete OGTT within 32 weeks gestation, or currently > 31 weeks gestation.
Description

Elig.phs000096.v4.p1.5

Type de données

boolean

Alias
UMLS CUI [1,1]
C1299582
UMLS CUI [1,2]
C0029161
UMLS CUI [1,3]
C0233039
Known multiple pregnancy.
Description

Elig.phs000096.v4.p1.6

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032989
Became pregnant with assistance of advanced reproductive technology such as in vitro fertilization (IVF) or superovulation with gonadotropins.
Description

Elig.phs000096.v4.p1.7

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0015915
UMLS CUI [1,3]
C0842347
Any unblinded blood glucose testing AND/OR diagnosis of GDM during this pregnancy prior to enrollment in this protocol.
Description

Elig.phs000096.v4.p1.8

Type de données

boolean

Alias
UMLS CUI [1,1]
C4553913
UMLS CUI [1,2]
C0392201
UMLS CUI [2,1]
C0011900
UMLS CUI [2,2]
C0085207
UMLS CUI [2,3]
C0332152
UMLS CUI [2,4]
C1516879
Previous diagnosis of diabetes requiring treatment with medication outside of pregnancy.
Description

Elig.phs000096.v4.p1.9

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011900
UMLS CUI [1,2]
C0011849
UMLS CUI [1,3]
C3274787
UMLS CUI [1,4]
C0332152
UMLS CUI [1,5]
C0032961
Currently receiving treatment with oral glucocorticoids, thiazide diuretics, -blockers, ACE inhibitors, oral -mimetics, dilantin, or antiretroviral agents.
Description

Elig.phs000096.v4.p1.10

Type de données

boolean

Alias
UMLS CUI [1,1]
C5223764
UMLS CUI [1,2]
C0017710
UMLS CUI [1,3]
C0012802
UMLS CUI [1,4]
C0003015
UMLS CUI [1,5]
C0699512
UMLS CUI [1,6]
C0599685
UMLS CUI [1,7]
C0001645
UMLS CUI [1,8]
C3846158
Participation in another study which may interfere with the HAPO Study.
Description

Elig.phs000096.v4.p1.11

Type de données

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2603343
Known to be HIV positive or to have Hepatitis B or C.
Description

Elig.phs000096.v4.p1.12

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019693
UMLS CUI [1,2]
C0019163
UMLS CUI [1,3]
C0019196
Participation in the HAPO Study during a previous pregnancy.
Description

Elig.phs000096.v4.p1.13

Type de données

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C0205156
UMLS CUI [1,4]
C0032961
Inability to converse in language(s) used in field center forms without the aid of an interpreter.
Description

Elig.phs000096.v4.p1.14

Type de données

boolean

Alias
UMLS CUI [1,1]
C4062227
*Note:* Women with any of the exclusion criteria present (except 11) were excluded since any of these criteria may confound study results. Women with criterion 11 present were excluded for protection of others since blood samples were transported across international borders.
Description

Elig.phs000096.v4.p1.15

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251

Similar models

Eligibility Criteria

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs000096.v4.p1.1
Item
A pregnant woman was *ineligible* to participate in HAPO if any of the following exclusion criteria applied:
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs000096.v4.p1.2
Item
Age < 18 years, i.e., has not completed 18th year of life by the first interview.
boolean
C1298908 (UMLS CUI [1,1])
C0001675 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,4])
C0021822 (UMLS CUI [1,5])
Elig.phs000096.v4.p1.3
Item
Planning to deliver at another hospital or location.
boolean
C1301732 (UMLS CUI [1,1])
C1384485 (UMLS CUI [1,2])
C1547118 (UMLS CUI [1,3])
Elig.phs000096.v4.p1.4
Item
Date of last menstrual period is not certain AND no ultrasound estimation from 6-24 weeks of gestational age is available or will be available.
boolean
C0425932 (UMLS CUI [1,1])
C0087130 (UMLS CUI [1,2])
C1298908 (UMLS CUI [1,3])
C0470187 (UMLS CUI [1,4])
C0041618 (UMLS CUI [1,5])
C4323880 (UMLS CUI [1,6])
C0730522 (UMLS CUI [1,7])
Elig.phs000096.v4.p1.5
Item
Unable to complete OGTT within 32 weeks gestation, or currently > 31 weeks gestation.
boolean
C1299582 (UMLS CUI [1,1])
C0029161 (UMLS CUI [1,2])
C0233039 (UMLS CUI [1,3])
Elig.phs000096.v4.p1.6
Item
Known multiple pregnancy.
boolean
C0032989 (UMLS CUI [1,1])
Elig.phs000096.v4.p1.7
Item
Became pregnant with assistance of advanced reproductive technology such as in vitro fertilization (IVF) or superovulation with gonadotropins.
boolean
C0032961 (UMLS CUI [1,1])
C0015915 (UMLS CUI [1,2])
C0842347 (UMLS CUI [1,3])
Elig.phs000096.v4.p1.8
Item
Any unblinded blood glucose testing AND/OR diagnosis of GDM during this pregnancy prior to enrollment in this protocol.
boolean
C4553913 (UMLS CUI [1,1])
C0392201 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C0085207 (UMLS CUI [2,2])
C0332152 (UMLS CUI [2,3])
C1516879 (UMLS CUI [2,4])
Elig.phs000096.v4.p1.9
Item
Previous diagnosis of diabetes requiring treatment with medication outside of pregnancy.
boolean
C0011900 (UMLS CUI [1,1])
C0011849 (UMLS CUI [1,2])
C3274787 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C0032961 (UMLS CUI [1,5])
Elig.phs000096.v4.p1.10
Item
Currently receiving treatment with oral glucocorticoids, thiazide diuretics, -blockers, ACE inhibitors, oral -mimetics, dilantin, or antiretroviral agents.
boolean
C5223764 (UMLS CUI [1,1])
C0017710 (UMLS CUI [1,2])
C0012802 (UMLS CUI [1,3])
C0003015 (UMLS CUI [1,4])
C0699512 (UMLS CUI [1,5])
C0599685 (UMLS CUI [1,6])
C0001645 (UMLS CUI [1,7])
C3846158 (UMLS CUI [1,8])
Elig.phs000096.v4.p1.11
Item
Participation in another study which may interfere with the HAPO Study.
boolean
C2348568 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2603343 (UMLS CUI [1,3])
Elig.phs000096.v4.p1.12
Item
Known to be HIV positive or to have Hepatitis B or C.
boolean
C0019693 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
Elig.phs000096.v4.p1.13
Item
Participation in the HAPO Study during a previous pregnancy.
boolean
C2348568 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
C0032961 (UMLS CUI [1,4])
Elig.phs000096.v4.p1.14
Item
Inability to converse in language(s) used in field center forms without the aid of an interpreter.
boolean
C4062227 (UMLS CUI [1,1])
Elig.phs000096.v4.p1.15
Item
*Note:* Women with any of the exclusion criteria present (except 11) were excluded since any of these criteria may confound study results. Women with criterion 11 present were excluded for protection of others since blood samples were transported across international borders.
boolean
C0680251 (UMLS CUI [1,1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial